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Abstract
The HOXB13 gene has been implicated in prostate cancer (PrCa) susceptibility. We performed a high resolution fine-
mapping analysis to comprehensively evaluate the association between common genetic variation across the HOXB genetic
locus at 17q21 and PrCa risk. This involved genotyping 700 SNPs using a custom Illumina iSelect array (iCOGS) followed by
imputation of 3195 SNPs in 20,440 PrCa cases and 21,469 controls in The PRACTICAL consortium. We identified a cluster of
highly correlated common variants situated within or closely upstream of HOXB13 that were significantly associated with
PrCa risk, described by rs117576373 (OR 1.30, P= 2.62610214). Additional genotyping, conditional regression and haplotype
analyses indicated that the newly identified common variants tag a rare, partially correlated coding variant in the HOXB13
gene (G84E, rs138213197), which has been identified recently as a moderate penetrance PrCa susceptibility allele. The
potential for GWAS associations detected through common SNPs to be driven by rare causal variants with higher relative
risks has long been proposed; however, to our knowledge this is the first experimental evidence for this phenomenon of
synthetic association contributing to cancer susceptibility.
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Introduction
Prostate cancer (PrCa) is the most common cancer affecting men
in developed countries, accounting for 25% of cancer diagnoses
among males in the UK in 2010 (http://www.cancerresearchuk.
org/cancer-info/cancerstats/types/prostate/incidence/).Whilst the
majority of men will develop some form of prostate neoplasm during
their lifetime, these are usually slow progressing and remain
asymptomatic until their death; therefore only a proportion of
prostate tumours require clinical intervention [1]. Currently,
prostate specific antigen (PSA) is the only available biomarker for
PrCa, however the specificity of this test for clinically significant
disease is poor and its use for PrCa screening remains controversial;
with little evidence of significant reduction in mortality and at the
cost of substantial overdiagnosis and overtreatment of patients [2,3].
Accordingly, much recent research has attempted to improve
identification of individuals at greater risk of developing prostate
tumours that require clinical intervention, to enable better
application of treatment. Twin studies have suggested that PrCa
has a substantial heritable component [4], whilst family history of
PrCa among first degree relatives remains among the strongest
known risk factors for the disease [5,6]. As a result, many studies
have looked for genetic variants that predispose towards the
development of PrCa. Relatively few moderate penetrance risk
variants for PrCa have been identified so far; however more than 70
common, low penetrance variants that individually modestly
increase risk have been identified to date through GWAS studies
[7,8].
We recently reported 23 novel PrCa susceptibility SNPs
identified through genotyping 20,440 PrCa cases and 21,469
controls from the PRACTICAL consortium on a custom Illumina
iSelect array (iCOGS) [7]. These SNPs were all from loci that had
shown some evidence for association with PrCa in our initial
GWAS [9]; however the iCOGS array also contained a subset of
SNPs that were included to examine possible associations with
plausible PrCa susceptibility candidate genes. HOX genes are
known to have crucial roles in development and previous evidence
suggested their potential involvement in oncogenesis [10],
including HOXB13 specifically in PrCa [11,12]. In addition, the
HOXB13 locus at chr17q21 was a region that had been previously
implicated in PrCa susceptibility by linkage studies [13–15] and
had been shown to undergo loss of heterozygosity in prostate
tumours [16–18]. As a result, we targeted the HOXB cluster at
chr17q21 to be densely genotyped on the iCOGS array. In
addition, a closely situated ovarian cancer risk association around
the SKAP1 gene [19] had also been targeted for fine-mapping by
the Ovarian Cancer Consortium (OCAC), providing additional
SNPs covering this chromosomal region.
Whilst genotyping on the iCOGS array was being performed,
Ewing et al. published evidence that a rare non-synonymous
coding variant in HOXB13 (G84E, rs138213197) was associated
with hereditary prostate cancer (HPC) [20]. This risk variant has
subsequently been confirmed to be a moderate penetrance
susceptibility allele in a number of other studies and it was shown
that the association was strongest with younger onset and familial
PrCa [21–23]. Additional studies examining the geographical
spread of the G84E variant have determined that it is observed
almost exclusively in Caucasians and predominantly on the same
haplotype background. This haplotype occurs more frequently in
Nordic countries, most strikingly within the Finnish population,
and suggests that rs138213197 is a founder mutation that arose
relatively recently in Northern Europe [24,25].
In this study, we show evidence that there is a cluster of novel
common, low penetrance PrCa risk alleles in the HOXB region
which appear to tag the rarer, moderate penetrance coding variant
Fine-Mapping the HOXB Region in Prostate Cancer
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rs138213197. To our knowledge, this represents the first identified
occurrence of a synthetic association in cancer.
Results
After QC, 700 SNPs from the interval Chr17:46201311–
47382559 (GRCh37/hg19) encompassing the HOXB locus were
analysed on the iCOGS array in 20,440 cases and 21,469 controls of
European ancestry from the PRACTICAL consortium. Two panel
imputation was performed for the interval Chr17:46200000–
47400000 using a 1000 Genomes Phase 1 integrated variant set
and Illumina OMNI2.5 BeadChip data for 677 PrCa cases from the
UKGPCS study. This generated imputed data for 3195 SNPs with
MAF$0.01 within this region in the iCOGS sample set. These
thresholds do not retain imputation information for the previously
reported coding variant (G84E, rs138213197) due to its low MAF.
As this SNP is a reported PrCa susceptibility variant and was in close
proximity to a cluster of variants showing association with PrCa risk
in our imputed data, additional genotyping was carried out by
Taqman and Sequenom assays for this SNP in 5500 cases and 4923
controls from the UK and Sweden. We subsequently attempted to
impute the rs138213197 variant to the entire iCOGS sample set
using this additional panel, however the imputation quality
remained inadequate and therefore analyses involving this variant
were performed on the directly genotyped subset of samples only.
Following imputation, four SNPs in close proximity to one
another and situated within or closely upstream of the HOXB13
gene remained significantly associated with PrCa at P,1026
(Table 1); of which one, rs117576373, had been genotyped on the
iCOGS array. This cluster of variants are highly correlated
(r2$0.79) and envelop the published missense coding variant
rs138213197 (G84E) (Figure 1). In the subset of samples that had
been genotyped for rs138213197, the correlation between
rs138213197 and the cluster of variants represented by
rs117576373 initially appears very modest (r2#0.13, Figure 1),
implying that the newly identified cluster of variants represented a
novel association signal. However, the MAFs of these variants are
substantially different (2.6–4.3% vs. 0.4% in our control set), with
the rare allele of rs138213197 (T) almost exclusively co-inherited
with the minor allele of rs117576373 (T) (D9 0.98). The nature of
the correlation between these variants could therefore be
consistent with rs117576373 representing an additional novel,
common, lower penetrance association signal at the HOXB13
region that is almost invariably present alongside the moderate
penetrance rs138213197 variant but is also found by itself in a
greater number of individuals. Alternatively, in spite of the low r2
between the two variants, the novel association signal could in fact
be tagging the rare G84E variant, thereby resulting in detection of
a synthetic association signal at a common variant that is in fact
mediated by a much rarer causal variant.
To elucidate which of these scenarios explain the PrCa risk
association at this locus we first performed a conditional regression
analysis for rs138213197 and the cluster of newly identified
variants, using the subset of cases that had been genotyped for
both rs138213197 and rs117576373. rs138213197 remained
highly significant in this analysis (P=4.2610212, Table 1) and
with an effect size substantially greater than that observed through
any of the common variants and broadly similar to that previously
reported in the literature (OR=3.88, 95%C.I. 2.64–5.70). This
suggests that the association with PrCa risk arises predominantly
through this rare coding variant. In addition, one of the more
common SNPs, rs145922598, also exhibited some evidence for
association (P=0.025). This SNP is somewhat less frequent than
the other three SNPs in the newly identified cluster, however is still
highly correlated with these (r2,0.8, D9,1) and is located in a
region of high conservation and functional context (Figure 1);
therefore could potentially represent a novel low penetrance
association signal. To further examine whether these variants
represent the same or separate association signals, in the subset of
samples in which the coding variant had been directly genotyped,
we conducted haplotype analyses between rs138213197 and
rs117576373 (both directly genotyped) and additionally between
rs138213197 and rs145922598 (imputed). This provides further
confirmation that rs138213197 is most likely responsible for PrCa
risk alone; since the moderately frequent rs138213197 (C, major
allele)–rs117576373 (T, minor allele) and rs138213197 (C, major
allele)–rs145922598 (T, minor allele) haplotypes showed no
evidence for association with disease risk, and a positive association
with risk was only observed in haplotypes where the rs138213197
(T, minor allele) risk allele was present (Tables 2 & 3).
In addition to this novel association signal, we also confirmed a
previously reported association within our imputation interval
described by rs11650494 in Caucasians [7] and rs7210100 in
African Americans [26]. This signal is situated .500 kb down-
stream of the novel variant cluster (Supplementary Figure S1),
around the ZNF652 gene. We observed no significant linkage
disequilibrium between these two clusters of variants (r2=0,
D9<0.02) and our conditional analysis confirmed that they
represent separate associations with PrCa.
Discussion
In this study, we identified a novel common PrCa association
signal at the HOXB13 locus. Further investigation revealed that
this signal is most likely to arise due to correlation with the
previously reported rare, moderate penetrance coding variant
rs138213197. Despite the fact that in this instance the rare,
putative causal variant was discovered prior to that of the more
common tag SNP, this PrCa susceptibility locus still serves as a
useful illustration of the potential range of causal variation
underpinning GWAS association signals, as well as the potential
pitfalls of attempting to elucidate candidate causal variants.
rs138213197 was discovered through re-sequencing of a PrCa
linkage hit at chr17q21 in hereditary prostate cancer (HPC)
families; although as we show here, it could instead have been
Author Summary
Genome-wide association studies (GWAS) have identified
numerous low penetrance disease susceptibility variants,
yet few causal alleles have been unambiguously identified.
The underlying causal variants are expected to be pre-
dominantly common; however synthetic associations with
rare, higher penetrance variants have been hypothesised
though not yet observed. Here, we report detection of a
novel common, low penetrance prostate cancer associa-
tion at the HOXB locus at ch17q and show that this signal
can actually be attributed to a previously identified rare,
moderate penetrance coding variant (G84E) in HOXB13.
This study therefore provides the first experimental
evidence for the existence of synthetic associations in
cancer and shows that where GWAS signals arise through
this phenomenon, risk predictions derived using the tag
SNP would substantially underestimate the relative risk
conferred and overestimate the number of carriers of the
causal variant. Synthetic associations at GWAS signals
could therefore account for a proportion of the missing
heritability of complex diseases.
Fine-Mapping the HOXB Region in Prostate Cancer
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indirectly detected through the modestly correlated variant
rs117576373 in a suitably powered GWAS study with sufficient
marker density such as the iCOGS study. Due to the large
difference in allele frequency between the tag and causal SNPs,
and the inability to accurately impute the rare variant even with a
priori knowledge of its existence, discovering this susceptibility locus
by this route would therefore disguise the contribution of the rare
variant and artificially diminish the observed relative risk; which
would consequently have implicated the likely causal variant(s) to
be relatively common, low penetrance and tightly correlated with
the typed SNP rs117576373. However, while we cannot
completely exclude that common variation may contribute to
PrCa risk at this locus as data from the ENCODE project suggests
some degree of potential functionality for the variants we have
identified here, (in particular rs145922598, which remained
marginally significant in the conditional regression, is highly
conserved, overlaps a DNaseI hypersensitivity site in several cell
lines including LNCaP and transcription factor binding sites for
FOXA1 and FOXA2 transcription factors (Table 1, Figure 1)); the
much stronger evidence for significance for the rare coding variant
coupled with the results of our haplotype analyses appear to
indicate that this SNP is solely responsible for the detected
association signal. As such, this appears to be an example of a rare
variant with a sufficiently large effect size to create a synthetic
association signal detected through partially correlated yet
significantly more common variants. It is also worth noting that
had the rs138213197 variant not been previously identified as a
PrCa susceptibility variant, it would have been unlikely to have
been discovered during this imputation based fine-mapping
approach since the MAF of this SNP is below conventional QC
thresholds for imputation; indeed, it remains poorly imputed even
using a two panel method in which a subset of samples had been
directly genotyped for this variant. The potential consequence of
this inability to accurately impute low frequency variants is that
the search for candidate causal variants for functional follow-up
would be inevitably skewed towards common variation. Further-
more, as we have observed here, where rare causal variants
underpin an association signal, risk effect size estimates may
consequently be significantly underestimated and the assumed
proportion of carriers of the causal variant inflated. Our
observations therefore provide support for the suggestion that
identifying the actual causal variants behind GWAS associations
could account for a proportion of the missing heritability in
common diseases and that re-sequencing of GWAS loci in large
numbers of cases and controls would be important for the
discovery of the full spectrum of correlated variation.
The nature of the underlying genetic architecture behind
GWAS signals has been the subject of much debate. Whilst few
causal alleles have been unambiguously categorised, several
authors have presented evidence that suggests common variants
are likely to comprise the vast majority of these [27–29].
Conversely, computational analyses have demonstrated that rare
causal variation has the potential capability to give rise to the
GWAS signals detected through more common variants [30–32].
For PrCa, fine-mapping and functional evidence at a handful of
risk loci appears to implicate common SNPs as the most likely
candidate causal variants at these regions. For example, at the
MSMB region at chr10q11, the common GWAS tag SNP situated
in the MSMB promoter remained the most plausible candidate
causal variant after fine-mapping by sequencing [33], with
functional studies also demonstrating that the risk allele disrupts
a transcription factor binding site, resulting in decreased expres-
sion of MSMB [34]. We have also performed fine-mapping studies
by imputation for the KLK region at chr19q13 and TERT locus at
chr5p15. We identified a common missense coding SNP in the
KLK3 gene that was more strongly associated with PrCa than the
original tag SNP and represents a candidate causal variant for this
association [35], whilst four independently associated clusters of
common variants were described at the TERT locus [36]; however
these studies were not powered to detect any contribution by rare
variants and despite refining the original associations, have not
unambiguously established the causal allele(s) at these regions.
This study therefore provides the first direct evidence of which we
are aware for a substantial contribution of rare variation to an
association signal for PrCa. This suggests that it is entirely
plausible that both mechanisms may indeed give rise to GWAS
Figure 1. Results of the HOXB locus fine-mapping analysis. Upper Panel – Regional association plot of SNPs at the HOXB13 locus. Association
data from the iCOGS dataset of 20,440 PrCa cases and 21,469 controls are shown with genotyped SNPs in red and imputed SNPs in green. The
Bonferroni-adjusted level of significance is denoted by the red line. The G84E variant rs138213197 was genotyped in a smaller subset of 5500 PrCa
cases and 4923 controls and is marked by the blue rectangle. Also indicated are the position of genes within this interval and the location of
neighbouring recombination hotspots. Middle Panel – Intersection between the 5 SNPs significantly associated with PrCa and putative functional
elements identified by the ENCODE project or regions of mammalian sequence conservation by PhyloP. Lower Panel – Pairwise Linkage
Disequilibrium values for the 5 SNPs significantly associated with PrCa. r2 values are shown in grey and D9 in red.
doi:10.1371/journal.pgen.1004129.g001
Table 1. PrCa association information for SNPs significant at P,1026 in the iCOGS imputed data.
SNP Pos (Chr17) MAF# Method
$
Uni P
$
Uni OR *Uni P *Uni OR *Multi P *Multi OR
rs116931900 46802314 0.038 Imputed 2.42610214 1.31 (1.22–1.40) 4.2261025 1.31 (1.15–1.50) 0.72 1.17 (0.50–2.73)
rs138213197 46805705 0.004 Typed - - 1.54610213 3.72 (2.62–5.27) 4.2610212 3.88 (2.64–5.70)
rs145922598 46810586 0.026 Imputed 2.25610214 1.38 (1.27–1.50) 4.9861024 1.31 (1.13–1.53) 0.025 1.50 (1.05–2.13)
rs4363897 46815947 0.039 Imputed 3.17610214 1.32 (1.23–1.42) 4.2361025 1.32 (1.16–1.52) 0.53 1.47 (0.45–4.86)
rs117576373 46820676 0.043 Typed 2.62610214 1.30 (1.22–1.40) 2.2861025 1.32 (1.16–1.52) 0.28 1.74 (0.64–4.71)
Uni denotes data from univariate analyses and Multi the results after conditional regression analysis. rs138213197 could not be accurately imputed into the iCOGS
sample set and was analysed in directly genotyped samples only.
#Minor Allele Frequency in our control sample set.
$
Analyses were performed on the full iCOGS data set of 20,440 cases and 21,469 controls.
*Analyses were performed on the subset of 5500 cases and 4923 controls genotyped for both rs138213197 and rs117576373.
doi:10.1371/journal.pgen.1004129.t001
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associations, and need not necessarily be mutually exclusive.
Logically however, the higher the MAF of the tag SNP at a
susceptibility locus the greater the likelihood that the associated
causal variant(s) will be common, whilst synthetic associations
would become increasingly plausible at lower index SNP MAFs (in
this study 2.6–4.3% MAF). Furthermore, whilst this study does
provide experimental evidence for the existence of synthetic
associations, no inference can be made as to how frequently they
might account for the causal variant behind the numerous disease
associations that GWAS have discovered. However, by capitalising
upon the differences in genetic architecture between different
ethnic populations in addition to the steadily increasing quantities
of sequencing data that are becoming available to the research
community, this may become more clear and help to guide future
fine-mapping studies. In particular, as the causal alleles behind
synthetic associations are rare, these associations are more likely to
be limited to specific ethnic groups and therefore the absence of a
multi-ethnic signal for a tag SNP of modest frequency could
indicate a greater likelihood that re-sequencing the locus would
identify rare causal variation.
In summary, this study provides evidence for several widely
discussed concepts regarding the nature of causal variation at
GWAS hits and their contribution to the heritability of common
diseases. Firstly, we have shown that low frequency, moderate
penetrance susceptibility variants can be detected via common tag
SNPs in GWAS studies when there is little recombination between
these variants. Secondly, that imputation based fine mapping
alone is likely to implicate candidate causal variants as common,
some of which may have plausible biological function; therefore
sufficiently powered re-sequencing of loci is ultimately desirable to
assess and possibly exclude the contribution of rare variants.
Finally, that for GWAS associations where the tag SNP is
correlated with a rare causal variant, the relative risk estimates
derived from the tag SNP are likely to be considerably
underestimated, which could in turn account for a proportion of
the missing heritability of common diseases.
Methods
Samples
Samples for the iCOGS study were drawn from 25 studies
participating in the PRACTICAL Consortium [7]. The majority
of studies were population-based or hospital-based case-control
studies, or nested case-control studies. All studies have the relevant
IRB approval in each country in accordance with the principles
embodied in the Declaration of Helsinki. After exclusion of
samples that failed quality control (QC) in the iCOGS study or
showed substantial non-European ancestry, genotype data for
20,440 PrCa cases and 21,469 matched controls were available.
To improve imputation performance, Illumina OMNI2.5 SNP
array data were available for 677 UK PrCa cases from the
UKGPCS study (www.icr.ac.uk/ukgpcs); 262 of these cases were
also genotyped on the iCOGS array. The rare coding variant
rs138213197 was also genotyped in 2476 cases and 2198 controls
from the UK (UKGPCS study), and 3024 cases and 2725 controls
from Sweden (CAPS and STHM1 study).
Genotyping
Detailed information relating to the custom iCOGS Illumina
Infinium array can be found in Eeles et al., 2013 [7]. With respect
to the HOXB locus, 747 SNPs spanning the interval
chr17:46201311–47382559 were genotyped on the iCOGS array,
submitted by a combination of the PRACTICAL and OCAC
consortia (Supplementary Figure S1).
To boost imputation performance, additional genotyping of 677
PrCa cases from the UK was conducted using the Illumina (San
Table 2. Haplotype analysis for rs117576373 and rs138213197 in the subset of 5500 PrCa cases and 4923 controls from the UK and
Sweden for which both had been directly genotyped.
rs117576373 rs138213197 Haplotype Case Freq Control Freq P OR
$
Empirical P
$
Corrected P
T T Minor | Minor 0.015 0.004 1.85610217 4.16 (2.91–5.94) 9.9961025 1.0061024
T C Minor | Major 0.038 0.037 0.74 1.02 (0.89–1.20) 0.74 1.00
C T Major | Minor 0 0 - - - -
C C Major | Major 0.947 0.959 3.661025 0.76 (0.67–0.87) 9.9961025 1.0061024
$
Empirical P values were generated after 1000 permutations testing of case control status. Corrected P values were subsequently generated from these by adjusting
for multiple testing.
doi:10.1371/journal.pgen.1004129.t002
Table 3. Haplotype analysis for rs145922598 and rs138213197 in the subset of 5500 PrCa cases and 4923 controls from the UK and
Sweden genotyped for rs138213197.
rs145922598 rs138213197 Haplotype Case Freq Control Freq P OR
$
Empirical P
$
Corrected P
T T Minor | Minor 0.015 0.004 7.47610215 3.76 (2.63–5.38) 1.0061024 1.0061024
T C Minor | Major 0.021 0.022 0.77 0.98 (0.87–1.11) 0.78 1.00
C T Major | Minor 0 0 - - - -
C C Major | Major 0.964 0.974 0.01 0.86 (0.77–0.97) 0.01 0.03
rs145922598 genotype information was extracted from our imputed dataset.
$
Empirical P values were generated after 1000 permutations testing of case control status. Corrected P values were subsequently generated from these by adjusting
for multiple testing.
doi:10.1371/journal.pgen.1004129.t003
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Diego, CA, USA) OMNI2.5 BeadChip according to the manu-
facturer’s instructions. Further genotyping of the rs138213197
variant was carried out by Taqman assay (Applied Biosystems Inc.,
Foster City, CA, USA) for 2476 cases and 2198 controls from the
UK and by MassARRAY iPLEX (Sequenom Inc., San Diego,
CA, USA) for 3024 cases and 2725 controls from Sweden.
Imputation
Imputation was performed on 20,440 case and 21,469 control
samples across the 700 iCOGS SNPs from the HOXB13 interval
which passed pre-imputation QC metrics [37] (Supplementary
Figure S2). IMPUTE v2.3.0 [38,39] was used to impute the
interval Chr17:46200000–47400000 (GRCh37/hg19). Two panel
imputation [40] was performed using OMNI2.5 BeadChip data
for 677 PrCa cases from the UKGPCS study (Panel 1) and a 1000
Genomes Phase 1 integrated variant set ‘‘version 3’’ (SNPs and in/
dels) from 5th March 2012 (Panel 0) (http://mathgen.stats.ox.ac.
uk/impute/data_download_1000G_phase1_integrated.html). Im-
putation concordance was examined using ‘‘leave one out’’
internal concordance check. For single panel imputation (Panel
0 only) concordance was 96.5% at SNPs r2$0.5 and 98.0% at
r2$0.9, which rose to 98.9% at r2$0.5 and 99.8% at r2$0.9
respectively for two panel (Panel 0+1) imputation. SNPs with info
,0.5, MAF,0.01 were excluded during QC filtering.
Statistical Analysis
Association tests were performed on genotypes in the MaCH
dosage format (0–2) converted from the IMPUTE genotype
posterior probabilities using GenABEL [41]. Associations between
each SNP and PrCa risk were analysed using a per-allele trend
test, adjusted for study and six principal components derived from
analysis of the whole iCOGS dataset [7]. Odds ratios (OR) and
95% confidence limits were estimated using unconditional logistic
regression. Tests of homogeneity of the ORs across strata were
assessed using a likelihood ratio test. SNPs significant at P,1026
were considered for further analysis. The independence of these
associations was assessed by performing a conditional logistic
regression analysis. For further assessment of the relationship
between rs138213197 and rs117576373, haplotype analyses
were performed with Plink 1.07 (http://pngu.mgh.harvard.edu/
purcell/plink/) on the subset of samples where both SNPs had
been directly genotyped. Haplotypes were first imputed using the
Expectation-Maximisation algorithm in order to then perform a
case-control association, using 10,000 permutations of the
phenotype labels [42].
Supporting Information
Figure S1 Distribution of genotyped SNPs at the HOXB locus
on chromosome 17 on the iCOGS array. The position of the
HOXB13 gene is indicated by the blue rectangle. Two clusters of
variants significantly associated with PrCa were identified. The
cluster marked in green represents a previously reported low
penetrance association signal described by the typed SNP
rs11650494 (Eeles et al., 2013, Nature Genetics) and are not
discussed further within the scope of this manuscript. The cluster
of four SNPs marked in red represented a novel association signal.
There is no significant linkage disequilibrium between these
clusters of variants (r2=0, D9<0.02).
(PNG)
Figure S2 Flowchart detailing the two panel imputation process
used to impute the HOXB locus at chromosome 17 in PrCa cases
and controls from the PRACTICAL consortium. The 1000
Genomes Project dataset used for imputation was a March 2012
‘‘version 3’’ of the Phase 1 integrated data.
(PNG)
Supplementary Information S1 List of members of consortia
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(DOCX)
Supplementary Information S2 Details of additional funding,
abbreviations and URLs.
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